{"id":53374,"date":"2023-01-27T14:02:31","date_gmt":"2023-01-27T13:02:31","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/qlaris-bio-to-present-at-glaucoma-360-new-horizons-forum\/"},"modified":"2023-01-27T14:02:31","modified_gmt":"2023-01-27T13:02:31","slug":"qlaris-bio-to-present-at-glaucoma-360-new-horizons-forum","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/qlaris-bio-to-present-at-glaucoma-360-new-horizons-forum\/","title":{"rendered":"Qlaris Bio to Present at Glaucoma 360 New Horizons Forum"},"content":{"rendered":"
\n

\nCEO Thurein Htoo to provide company update and share plans for coming year<\/i>\n<\/p>\n

DEDHAM, Mass.–(BUSINESS WIRE)–Qlaris Bio, Inc.<\/a>, a biotechnology company targeting high unmet needs in debilitating ophthalmic diseases, announced today that Thurein Htoo, MS, MBA, the company\u2019s co-founder and chief executive officer, will present during the 12th Annual Glaucoma 360 New Horizons Forum on Friday, Feb. 3, 2023, at 8:40 a.m. PT (11:40 a.m. ET) in San Francisco.\n<\/p>\n

<\/a><\/p>\n

\nHtoo will participate in the session titled \u201cDelivering Glaucoma Solutions\u201d and will provide updates on Qlaris Bio\u2019s plans for 2023 and the company\u2019s novel ATP-sensitive potassium (KATP<\/sub>) channel modulator platform currently in development to treat a range of glaucomas, including normal tension glaucoma (NTG), primary open-angle glaucoma (POAG), and glaucoma related to rare diseases such as Sturge-Weber Syndrome.\n<\/p>\n

\n\u201cIt is an exciting time for Qlaris and the future of glaucoma therapy,\u201d said Htoo. \u201cOur company is developing a treatment focused on reducing episcleral venous pressure (EVP), which is not a primary target of existing glaucoma therapies, despite being a significant component of intraocular pressure (IOP). I am looking forward to sharing updates on Qlaris\u2019 program and our anticipated milestones for the coming year.\u201d\n<\/p>\n

\nThe Glaucoma 360 New Horizons Forum is hosted by the Glaucoma Research Foundation and brings together clinical, industry, financial, and FDA leaders to discuss research innovation and advances in glaucoma treatment. Register for the event here<\/a>.\n<\/p>\n

\nAbout Qlaris Bio, Inc.
\n
<\/b>Qlaris Bio, Inc., was founded in August 2019 with a singular focus: to develop novel, innovative therapies with first-in-class mechanisms of action to address serious and debilitating ophthalmic diseases. The company\u2019s lead platform is based on the use of adenosine triphosphate (ATP)-sensitive potassium (KATP<\/sub>) channel modulators to affect the tone of vascular and vascular-like tissues for ophthalmic use. Qlaris Bio\u2019s investors include Canaan and New Leaf Venture Partners, both of which were co-lead investors in the company\u2019s $25 million Series A round in August 2019. Other investors include Correlation Ventures and Mayo Clinic. For more information, please visit qlaris.bio<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Contact<\/b>
Matt Pera
\n
973-886-9150
\n
matt.pera@smithsolve.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

CEO Thurein Htoo to provide company update and share plans for coming year DEDHAM, Mass.–(BUSINESS WIRE)–Qlaris Bio, Inc., a biotechnology company targeting high unmet needs in debilitating ophthalmic diseases, announced today that Thurein Htoo, MS, MBA, the company\u2019s co-founder and chief executive officer, will present during the 12th Annual Glaucoma 360 New Horizons Forum on … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53374","6":"format-standard","7":"category-industry"},"yoast_head":"\nQlaris Bio to Present at Glaucoma 360 New Horizons Forum - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/qlaris-bio-to-present-at-glaucoma-360-new-horizons-forum\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Qlaris Bio to Present at Glaucoma 360 New Horizons Forum - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"CEO Thurein Htoo to provide company update and share plans for coming year DEDHAM, Mass.–(BUSINESS WIRE)–Qlaris Bio, Inc., a biotechnology company targeting high unmet needs in debilitating ophthalmic diseases, announced today that Thurein Htoo, MS, MBA, the company\u2019s co-founder and chief executive officer, will present during the 12th Annual Glaucoma 360 New Horizons Forum on ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/qlaris-bio-to-present-at-glaucoma-360-new-horizons-forum\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-27T13:02:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230127005073\/en\/1697872\/21\/Qlaris_Primary_Logo_Stacked.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/qlaris-bio-to-present-at-glaucoma-360-new-horizons-forum\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/qlaris-bio-to-present-at-glaucoma-360-new-horizons-forum\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Qlaris Bio to Present at Glaucoma 360 New Horizons Forum\",\"datePublished\":\"2023-01-27T13:02:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/qlaris-bio-to-present-at-glaucoma-360-new-horizons-forum\\\/\"},\"wordCount\":354,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/qlaris-bio-to-present-at-glaucoma-360-new-horizons-forum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230127005073\\\/en\\\/1697872\\\/21\\\/Qlaris_Primary_Logo_Stacked.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/qlaris-bio-to-present-at-glaucoma-360-new-horizons-forum\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/qlaris-bio-to-present-at-glaucoma-360-new-horizons-forum\\\/\",\"name\":\"Qlaris Bio to Present at Glaucoma 360 New Horizons Forum - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/qlaris-bio-to-present-at-glaucoma-360-new-horizons-forum\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/qlaris-bio-to-present-at-glaucoma-360-new-horizons-forum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230127005073\\\/en\\\/1697872\\\/21\\\/Qlaris_Primary_Logo_Stacked.jpg\",\"datePublished\":\"2023-01-27T13:02:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/qlaris-bio-to-present-at-glaucoma-360-new-horizons-forum\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/qlaris-bio-to-present-at-glaucoma-360-new-horizons-forum\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/qlaris-bio-to-present-at-glaucoma-360-new-horizons-forum\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230127005073\\\/en\\\/1697872\\\/21\\\/Qlaris_Primary_Logo_Stacked.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230127005073\\\/en\\\/1697872\\\/21\\\/Qlaris_Primary_Logo_Stacked.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/qlaris-bio-to-present-at-glaucoma-360-new-horizons-forum\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Qlaris Bio to Present at Glaucoma 360 New Horizons Forum\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Qlaris Bio to Present at Glaucoma 360 New Horizons Forum - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/qlaris-bio-to-present-at-glaucoma-360-new-horizons-forum\/","og_locale":"en_US","og_type":"article","og_title":"Qlaris Bio to Present at Glaucoma 360 New Horizons Forum - Pharma Trend","og_description":"CEO Thurein Htoo to provide company update and share plans for coming year DEDHAM, Mass.–(BUSINESS WIRE)–Qlaris Bio, Inc., a biotechnology company targeting high unmet needs in debilitating ophthalmic diseases, announced today that Thurein Htoo, MS, MBA, the company\u2019s co-founder and chief executive officer, will present during the 12th Annual Glaucoma 360 New Horizons Forum on ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/qlaris-bio-to-present-at-glaucoma-360-new-horizons-forum\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-27T13:02:31+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230127005073\/en\/1697872\/21\/Qlaris_Primary_Logo_Stacked.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/qlaris-bio-to-present-at-glaucoma-360-new-horizons-forum\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/qlaris-bio-to-present-at-glaucoma-360-new-horizons-forum\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Qlaris Bio to Present at Glaucoma 360 New Horizons Forum","datePublished":"2023-01-27T13:02:31+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/qlaris-bio-to-present-at-glaucoma-360-new-horizons-forum\/"},"wordCount":354,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/qlaris-bio-to-present-at-glaucoma-360-new-horizons-forum\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230127005073\/en\/1697872\/21\/Qlaris_Primary_Logo_Stacked.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/qlaris-bio-to-present-at-glaucoma-360-new-horizons-forum\/","url":"https:\/\/pharma-trend.com\/en\/qlaris-bio-to-present-at-glaucoma-360-new-horizons-forum\/","name":"Qlaris Bio to Present at Glaucoma 360 New Horizons Forum - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/qlaris-bio-to-present-at-glaucoma-360-new-horizons-forum\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/qlaris-bio-to-present-at-glaucoma-360-new-horizons-forum\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230127005073\/en\/1697872\/21\/Qlaris_Primary_Logo_Stacked.jpg","datePublished":"2023-01-27T13:02:31+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/qlaris-bio-to-present-at-glaucoma-360-new-horizons-forum\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/qlaris-bio-to-present-at-glaucoma-360-new-horizons-forum\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/qlaris-bio-to-present-at-glaucoma-360-new-horizons-forum\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230127005073\/en\/1697872\/21\/Qlaris_Primary_Logo_Stacked.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230127005073\/en\/1697872\/21\/Qlaris_Primary_Logo_Stacked.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/qlaris-bio-to-present-at-glaucoma-360-new-horizons-forum\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Qlaris Bio to Present at Glaucoma 360 New Horizons Forum"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53374","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53374"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53374\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53374"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53374"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53374"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}